Literature DB >> 34902548

Three-Month Follow-Up Results of a Double-Blind, Randomized Placebo-Controlled Trial of 8-Week Self-Administered At-Home Behavioral Skills-Based Virtual Reality (VR) for Chronic Low Back Pain.

Laura M Garcia1, Brandon J Birckhead2, Parthasarathy Krishnamurthy3, Ian Mackey4, Josh Sackman4, Vafi Salmasi5, Robert Louis6, Todd Maddox4, Beth D Darnall7.   

Abstract

Prior work established post-treatment efficacy for an 8-week home-based therapeutic virtual reality (VR) program in a double-blind, parallel arm, randomized placebo-controlled study. Participants were randomized 1:1 to 1 of 2 56-day VR programs: 1) a therapeutic immersive pain relief skills VR program; or 2) a Sham VR program within an identical commercial VR headset. Immediate post-treatment results demonstrated clinically meaningful and superior reduction for therapeutic VR compared to Sham VR for average pain intensity, indices of pain-related interference (activity, mood, stress but not sleep), physical function, and sleep disturbance. The objective of the current report was to quantify treatment effects to post-treatment month 3 and describe durability of effects. Intention-to-treat analyses revealed sustained benefits for both groups and superiority for therapeutic VR for pain intensity and multiple indices of pain-related interference (activity, stress, and newly for sleep; effect sizes ranged from drm = .56-.88) and physical function from pre-treatment to post-treatment month 3. The between-group difference for sleep disturbance was non-significant and pain-interference with mood did not survive multiplicity correction at 3 months. For most primary and secondary outcomes, treatment effects for therapeutic VR showed durability, and maintained superiority to Sham VR in the 3-month post-treatment period. PERSPECTIVE: We present 3-month follow-up results for 8-week self-administered therapeutic virtual reality (VR) compared to Sham VR in adults with chronic low back pain. Across multiple pain indices, therapeutic VR had clinically meaningful benefits, and superiority over Sham VR. Home-based, behavioral skills VR yielded enduring analgesic benefits; longer follow-up is needed.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Behavioral health; chronic low back pain; randomized controlled trial; treatment; virtual reality

Mesh:

Year:  2021        PMID: 34902548     DOI: 10.1016/j.jpain.2021.12.002

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  4 in total

Review 1.  Adjunct Digital Interventions Improve Opioid-Based Pain Management: Impact of Virtual Reality and Mobile Applications on Patient-Centered Pharmacy Care.

Authors:  Hayam Y Giravi; Zack Biskupiak; Linda S Tyler; Grzegorz Bulaj
Journal:  Front Digit Health       Date:  2022-06-13

2.  Evaluation Challenges for the Application of Extended Reality Devices in Medicine.

Authors:  Ryan Beams; Ellenor Brown; Wei-Chung Cheng; Janell S Joyner; Andrea S Kim; Kimberly Kontson; Dimitri Amiras; Tassilo Baeuerle; Walter Greenleaf; Rafael J Grossmann; Atul Gupta; Christoffer Hamilton; Hong Hua; Tran Tu Huynh; Christoph Leuze; Sarah B Murthi; John Penczek; Jennifer Silva; Brennan Spiegel; Amitabh Varshney; Aldo Badano
Journal:  J Digit Imaging       Date:  2022-04-25       Impact factor: 4.903

3.  Durability of the Treatment Effects of an 8-Week Self-administered Home-Based Virtual Reality Program for Chronic Low Back Pain: 6-Month Follow-up Study of a Randomized Clinical Trial.

Authors:  Laura Garcia; Brandon Birckhead; Parthasarathy Krishnamurthy; Ian Mackey; Josh Sackman; Vafi Salmasi; Robert Louis; Carina Castro; Roselani Maddox; Todd Maddox; Beth D Darnall
Journal:  J Med Internet Res       Date:  2022-05-25       Impact factor: 7.076

4.  Effect of Virtual Reality Hypnosis on Pain Threshold and Neurophysiological and Autonomic Biomarkers in Healthy Volunteers: Prospective Randomized Crossover Study.

Authors:  Claire Terzulli; Meggane Melchior; Edouard Laroche; Chloé Chauvin; Pierrick Poisbeau; Laurent Goffin; Sylvain Faisan; Coralie Gianesini; Denis Graff; André Dufour
Journal:  J Med Internet Res       Date:  2022-07-29       Impact factor: 7.076

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.